- Home
- RLAY
as 07-26-2024 4:00pm EST
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 1.0B | IPO Year: | 2020 |
| Target Price: | $21.60 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.64 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.70 - $12.63 | Next Earning Date: | 08-06-2024 |
| Revenue: | $35,327,000 | Revenue Growth: | 2873.65% |
| Revenue Growth (this year): | -59.15% | Revenue Growth (next year): | -27.85% |
Stock Insider Trading Activity of Relay Therapeutics Inc. (RLAY)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Adams Brian | RLAY | Chief Legal Officer | Jun 27 '24 | Sell | $6.26 | 295 | $1,846.70 | 325,472 | SEC Form 4 |
| Catinazzo Thomas | RLAY | Chief Financial Officer | Jun 27 '24 | Sell | $6.24 | 9,078 | $56,646.72 | 330,430 | SEC Form 4 |
| Catinazzo Thomas | RLAY | Chief Financial Officer | Jun 27 '24 | Sell | $6.26 | 295 | $1,846.70 | 339,508 | SEC Form 4 |
| Bergstrom Donald A | RLAY | President, R&D | Jun 27 '24 | Sell | $6.26 | 648 | $4,056.48 | 526,779 | SEC Form 4 |
| Rahmer Peter | RLAY | See remarks | Jun 27 '24 | Sell | $6.26 | 245 | $1,533.70 | 432,180 | SEC Form 4 |
| Rahmer Peter | RLAY | See remarks | Jun 3 '24 | Sell | $6.47 | 19,864 | $128,520.08 | 493,470 | SEC Form 4 |
| Rahmer Peter | RLAY | See remarks | Jun 3 '24 | Sell | $6.64 | 40,595 | $269,550.80 | 452,875 | SEC Form 4 |
| Rahmer Peter | RLAY | See remarks | Jun 3 '24 | Sell | $7.06 | 20,450 | $144,377.00 | 432,425 | SEC Form 4 |
| Adams Brian | RLAY | Chief Legal Officer | Apr 29 '24 | Sell | $6.38 | 1,623 | $10,354.74 | 325,767 | SEC Form 4 |
| Bergstrom Donald A | RLAY | President, R&D | Apr 29 '24 | Sell | $6.38 | 2,686 | $17,136.68 | 527,427 | SEC Form 4 |
| Catinazzo Thomas | RLAY | Chief Financial Officer | Apr 29 '24 | Sell | $6.38 | 1,695 | $10,814.10 | 339,803 | SEC Form 4 |
| Rahmer Peter | RLAY | See remarks | Apr 29 '24 | Sell | $6.38 | 1,345 | $8,581.10 | 513,334 | SEC Form 4 |
| Bergstrom Donald A | RLAY | President, R&D | Mar 27 '24 | Sell | $7.70 | 765 | $5,890.50 | 530,113 | SEC Form 4 |
| Rahmer Peter | RLAY | See remarks | Mar 27 '24 | Sell | $7.70 | 298 | $2,294.60 | 514,679 | SEC Form 4 |
| Adams Brian | RLAY | Chief Legal Officer | Mar 27 '24 | Sell | $7.70 | 348 | $2,679.60 | 327,390 | SEC Form 4 |
| Catinazzo Thomas | RLAY | Chief Financial Officer | Mar 27 '24 | Sell | $7.70 | 348 | $2,679.60 | 341,498 | SEC Form 4 |
| Rahmer Peter | RLAY | See remarks | Jan 29 '24 | Sell | $9.64 | 1,651 | $15,915.64 | 514,977 | SEC Form 4 |
| Catinazzo Thomas | RLAY | Chief Financial Officer | Jan 29 '24 | Sell | $9.64 | 2,005 | $19,328.20 | 341,846 | SEC Form 4 |
| Adams Brian | RLAY | Chief Legal Officer | Jan 29 '24 | Sell | $9.64 | 1,929 | $18,595.56 | 327,738 | SEC Form 4 |
| Bergstrom Donald A | RLAY | President, R&D | Jan 29 '24 | Sell | $9.64 | 3,178 | $30,635.92 | 530,878 | SEC Form 4 |
| Rahmer Peter | RLAY | See remarks | Dec 27 '23 | Sell | $11.51 | 244 | $2,808.44 | 316,628 | SEC Form 4 |
| Bergstrom Donald A | RLAY | President, R&D | Dec 27 '23 | Sell | $11.51 | 977 | $11,245.27 | 234,056 | SEC Form 4 |
| Adams Brian | RLAY | Chief Legal Officer | Dec 27 '23 | Sell | $11.51 | 294 | $3,383.94 | 129,667 | SEC Form 4 |
| Catinazzo Thomas | RLAY | Chief Financial Officer | Dec 27 '23 | Sell | $11.51 | 294 | $3,383.94 | 143,851 | SEC Form 4 |
Latest Relay Therapeutics Inc. News
RLAY Breaking Stock News: Dive into RLAY Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
We're Not Very Worried About Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Rate
MT Newswires
8 days ago
JMP Securities Cuts Price Target on Relay Therapeutics to $21 From $24, Maintains Market Outperform Rating
MT Newswires
9 days ago
HC Wainwright Adjusts Price Target on Relay Therapeutics to $18 From $20, Maintains Buy Rating
BioPharma Dive
10 days ago
Caribou lays off staff; Roche walks away from Relay
MT Newswires
10 days ago
Relay Therapeutics Get Collaboration, License Deal Terminated With Genentech
GlobeNewswire
2 months ago
$6.6 Billion Digital X-ray Market, 2024-2029: Development of AI-based Digital X-Ray Systems Present Business Opportunities
Motley Fool
2 months ago
2 Reasons to Buy Rivian Stock (and 1 Big Reason to Sell)
CNW Group
2 months ago
DFR Gold Inc. Announces Amendment of WUO Land Option and Insider Loans
Compare RLAY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RLAY Relay Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.